Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Nuvectis Pharma, Inc.

NVCT · Nasdaq · CIK 0001875558 · Healthcare · Biotechnology

INSIDER SIGNAL

56.8 / 100

2 buyers · 2 purchase transaction lines · $1.2M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+18.2 / 25
Role+13.0 / 20
Recency+1.6 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Chairman & CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Hoberman KennethDirector
○
Oliviero James F IIIDirector
○
Sanchez JuanDirector
○
Kaplan Matthew L.Director
○
Carson Michael J.Vice President, Finance
○
Mosseri Marlio CharlesTenPercentOwner
●
● Purchase▼ Sale○ Other

Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION79%Largest buyer: Mosseri Marlio Charles · $916.0K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-06-30–2026-06-30

Roles in the peak window: Chairman & CEO, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

56.8 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 57.0
  2. 57.0
  3. 57.0
  4. 56.8
  5. 56.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

8Purchases
0Sales
9Other Form 4 lines
15SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER5 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-6.1%
3M
+14.5%
6M
+156.9%
12M
+239.0%

Volatility & liquidity

Volatility
90.4%
Beta
—
Avg daily value
USD 4.5M

Valuation

Market cap
USD 688.1M
P/E
—

Fundamentals

Profit margin
—
ROE
-143.6%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
2,522,106
Previous report
2,362,527
Avg daily volume
243,827
Days to cover
10.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-30Mosseri Marlio CharlesPurchase (P)Common Stock50,000USD 18.32USD 916,000SEC filing ↗
2026-06-30BENTSUR RONPurchase (P)Common Stock12,500USD 20.00USD 250,000SEC filing ↗
2025-11-05Sanchez JuanPurchase (P)Common Stock13,000USD 5.79USD 75,270SEC filing ↗
2025-11-05Kaplan Matthew L.Purchase (P)Common Stock11,000USD 5.84USD 64,240SEC filing ↗
2025-11-05BENTSUR RONPurchase (P)Common Stock5,000USD 5.72USD 28,600SEC filing ↗
2025-10-27Mosseri Marlio CharlesPurchase (P)Common Stock72,836USD 6.28USD 457,410SEC filing ↗
2025-10-24Mosseri Marlio CharlesPurchase (P)Common Stock35,034USD 6.15USD 215,459SEC filing ↗
2025-10-23Mosseri Marlio CharlesPurchase (P)Common Stock46,900USD 6.06USD 284,214SEC filing ↗
2025-06-20Mosseri Marlio CharlesPurchase (P)Common Stock5,603USD 7.99USD 44,768SEC filing ↗
2025-06-18Mosseri Marlio CharlesPurchase (P)Common Stock28,043USD 8.05USD 225,746SEC filing ↗
2025-06-17Mosseri Marlio CharlesPurchase (P)Common Stock5,399USD 8.11USD 43,786SEC filing ↗
2025-05-12Mosseri Marlio CharlesPurchase (P)Common Stock21,167USD 8.11USD 171,664SEC filing ↗
2025-05-09Mosseri Marlio CharlesPurchase (P)Common Stock25,062USD 8.94USD 223,976SEC filing ↗
2025-05-08Mosseri Marlio CharlesPurchase (P)Common Stock2,600USD 8.96USD 23,298SEC filing ↗
2025-05-08Mosseri Marlio CharlesPurchase (P)Common Stock2,550USD 8.65USD 22,058SEC filing ↗

Form 4 evidence

17 transaction lines in the latest 365-day window; 186 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-03Carson Michael J.Award / grant (A)Common Stock30,000USD 0.00USD 0SEC filing ↗
2026-06-30Mosseri Marlio CharlesPurchase (P)Common Stock50,000USD 18.32USD 916,000SEC filing ↗
2026-06-30BENTSUR RONPurchase (P)Common Stock12,500USD 20.00USD 250,000SEC filing ↗
Show recent Form 4 evidence (17 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-03Carson Michael J.Award / grant (A)Common Stock30,000USD 0.00USD 0SEC filing ↗
2026-06-30Mosseri Marlio CharlesPurchase (P)Common Stock50,000USD 18.32USD 916,000SEC filing ↗
2026-06-30BENTSUR RONPurchase (P)Common Stock12,500USD 20.00USD 250,000SEC filing ↗
2026-06-11Sanchez JuanAward / grant (A)Common Stock35,000USD 0.00USD 0SEC filing ↗
2026-06-11Oliviero James F IIIAward / grant (A)Common Stock35,000USD 0.00USD 0SEC filing ↗
2026-06-11Kaplan Matthew L.Award / grant (A)Common Stock35,000USD 0.00USD 0SEC filing ↗
2026-06-11Hoberman KennethAward / grant (A)Common Stock35,000USD 0.00USD 0SEC filing ↗
2026-01-06Shemesh ShayAward / grant (A)Common Stock150,000USD 0.00USD 0SEC filing ↗
2026-01-06Poradosu EnriqueAward / grant (A)Common Stock150,000USD 0.00USD 0SEC filing ↗
2026-01-06Carson Michael J.Award / grant (A)Common Stock61,200USD 0.00USD 0SEC filing ↗
2026-01-06BENTSUR RONAward / grant (A)Common Stock150,000USD 0.00USD 0SEC filing ↗
2025-11-05Sanchez JuanPurchase (P)Common Stock13,000USD 5.79USD 75,270SEC filing ↗
2025-11-05Kaplan Matthew L.Purchase (P)Common Stock11,000USD 5.84USD 64,240SEC filing ↗
2025-11-05BENTSUR RONPurchase (P)Common Stock5,000USD 5.72USD 28,600SEC filing ↗
2025-10-27Mosseri Marlio CharlesPurchase (P)Common Stock72,836USD 6.28USD 457,410SEC filing ↗
2025-10-24Mosseri Marlio CharlesPurchase (P)Common Stock35,034USD 6.15USD 215,459SEC filing ↗
2025-10-23Mosseri Marlio CharlesPurchase (P)Common Stock46,900USD 6.06USD 284,214SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNVCT
CIK0001875558
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history186 transaction lines from 2022-02-04 to 2026-08-03
152 P purchase lines · 1 S sale lines · 33 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.